Literature DB >> 30258467

Absorption Characteristics of Combination Medication of Realgar and Indigo Naturalis: In Vitro Transport across MDCK-MDR1 Cells and In Vivo Pharmacokinetics in Mice after Oral Administration.

Miao Zhang1, Lin Guo2, Long-Fei Lin3, Chang-Hai Qu2, Xing-Bin Yin2, Shi-Lin Luo2, Xin Zhang2, Hai-Ying Zhang2, Xiao Liang4, Jun Guan2, Jian Ni2,5.   

Abstract

Realgar and indigo naturalis are clinically combined to treat varieties of leukemia. Exploring the drug-drug interactions might be beneficial to find active substances and develop new targeted drugs. This study aimed at exploring the change of arsenic concentration in mice and across MDCK-MDR1 cells and the cytotoxicity on K562 cells when realgar and indigo naturalis were combined. In the presence or absence of indigo naturalis, pharmacokinetics and cell-based permeability assays were used to evaluate the change of arsenic concentration, and K562 cell line was applied to evaluate the change of cytotoxicity. The drug concentration-time profiles exhibited that the combination medication group generated higher AUC, thalf, and longer MRT for arsenic, compared with the single administration of realgar. The apparent permeability coefficients (Papp) of bidirectional transport in MDCK-MDR1 cell permeability experiments showed that arsenic permeability obviously went up when indigo naturalis was incubated together. The combination medication significantly decreased the cell viability of K562 cells when both the concentration of realgar and the concentration of indigo naturalis were nontoxic. The pharmacokinetic research, the MDCK-MDR1 based permeability study, and the K562 cytotoxicity study were united together to verify the combination medication of realgar and indigo naturalis enhanced the absorption and the permeability across cells for arsenic and effectively inhibited the proliferation of K562 cell line. The molecular binding of As4S4 and indirubin was analyzed by computational study. It is predicted that the formation of the complex [As4S4Indirubin] involves noncovalent interaction that changes the concentration of arsenic.

Entities:  

Year:  2018        PMID: 30258467      PMCID: PMC6146668          DOI: 10.1155/2018/6493630

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


  24 in total

1.  In vitro model for evaluating drug transport across the blood-brain barrier.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

Review 2.  Cardiac toxicity of arsenic trioxide.

Authors:  J T Barbey
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

3.  Binding of dimethylarsinous acid to cys-13alpha of rat hemoglobin is responsible for the retention of arsenic in rat blood.

Authors:  Meiling Lu; Hailin Wang; Xing-Fang Li; Lora L Arnold; Samuel M Cohen; X Chris Le
Journal:  Chem Res Toxicol       Date:  2007-01       Impact factor: 3.739

Review 4.  Potentiating therapeutic effects by enhancing synergism based on active constituents from traditional medicine.

Authors:  Aihua Zhang; Hui Sun; Xijun Wang
Journal:  Phytother Res       Date:  2013-08-01       Impact factor: 5.878

5.  Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder.

Authors:  Shu Xu; Rou Ma; Xiao-Mei Hu; Yong-Gang Xu; Xiao-Hong Yang; Hong-Zhi Wang; Shu-Zhen Sun; Feng Liu
Journal:  Chin J Integr Med       Date:  2011-11-06       Impact factor: 1.978

6.  Evidence against the participation of a pharmacokinetic interaction in the protective effect of single-dose curcumin against gastrointestinal damage induced by indomethacin in rats.

Authors:  Liliana Zazueta-Beltrán; Lorena Medina-Aymerich; Nadia Estela Díaz-Triste; Aracely Evangelina Chávez-Piña; Gilberto Castañeda-Hernández; Leticia Cruz-Antonio
Journal:  J Integr Med       Date:  2017-03

Review 7.  Current study of APL treatment in China.

Authors:  Dao-Pei Lu; Qin Wang
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Authors:  R Hoessel; S Leclerc; J A Endicott; M E Nobel; A Lawrie; P Tunnah; M Leost; E Damiens; D Marie; D Marko; E Niederberger; W Tang; G Eisenbrand; L Meijer
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

Review 9.  Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

Authors:  A List; M Beran; J DiPersio; J Slack; N Vey; C S Rosenfeld; P Greenberg
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

10.  Prolonged Survival of Acute Lymphoblastic Leukemia with Intrathecal Treatments for Isolated Central Nervous System Relapse.

Authors:  Elan Gorshein; Sheila Kalathil; Mecide Gharibo
Journal:  Case Rep Hematol       Date:  2018-01-31
View more
  4 in total

1.  Arsenic Accumulation of Realgar Altered by Disruption of Gut Microbiota in Mice.

Authors:  Wenfeng Xu; Shanshan Zhang; Wenqing Jiang; Shuo Xu; Pengfei Jin
Journal:  Evid Based Complement Alternat Med       Date:  2020-08-18       Impact factor: 2.629

2.  Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.

Authors:  Qianqian Huang; Tao Wang; Yan Xiong; Liping Qu; Qiaozhi Yin; Wenjun Zou
Journal:  Chin Herb Med       Date:  2021-09-13

Review 3.  Pharmacology, Toxicology, and Rational Application of Cinnabar, Realgar, and Their Formulations.

Authors:  Huifang Guan; Yan Xu; Chunyu Ma; Dexi Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-27       Impact factor: 2.650

4.  Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials.

Authors:  Yi-Ming Chen; Jie-Min Deng; Yi Wen; Bin Chen; Jiang-Tao Hou; Bin Peng; Shi-Jing Zhang; Hong Mi; Qi-Long Jiang; Xia-Lin Wu; Feng-Bin Liu; Xin-Lin Chen
Journal:  Trials       Date:  2020-05-12       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.